Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... That is, most of the atoms in our ... in the outer parts of atoms equals the number ... one or more electrons are plucked away from the ... pull from the nucleus. This enhanced pull, causing ... electrons are less vulnerable to the distractions of their ...
(Date:7/18/2014)... , July 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... of Directors appointed Co-Chairmen Charles S. Ramat ... on an interim basis, effective immediately. Messrs. Ramat and ... no longer Chief Executive Officer of Neurotrope Bioscience, Inc., ... and whose employment agreement with Neurotrope Bioscience Inc. terminated ...
(Date:7/18/2014)... Emerging Nuclear Power Countries - Market Forecast, ... , The latest report from GlobalData, Emerging Nuclear Power ... to 2030 covers the emerging nuclear market and the ... on key market players and their global market share. ... across the world has also been estimated. , To ...
Breaking Biology Technology:Highly charged ions 2Highly charged ions 3Highly charged ions 4Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3
... electrical hair that lets them link up in ... Southern California biophysicist and his collaborators. The ... and share energy in part through electrically conducting ... the first measurement of electron transport along biological ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... product candidate, fidaxomicin, will be presented ... Disease Society of America (IDSA) to be held at ... on October 21-24, 2010. (Logo: ...
... N.J. Physicists at Rutgers University have discovered new ... and inexpensive plastic solar cells for pollution-free electricity production. ... in an upcoming issue of the journal Nature ... of light can travel on the order of a ...
Cached Biology Technology:Microbial hair: It's electric 2Microbial hair: It's electric 3Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2
(Date:7/21/2014)... has issued a high health risk warning for Yellowknife ... region due to forest fires. Currently 160 wildfires ... plans for evacuation since these fires are endangering people ... area recently comes with mixed results. The rains ... to start others. , This year the Northern Territories ...
(Date:7/21/2014)... School of Medicine-led study suggests that parents of obese ... consequences of childhood weight gain or the importance of ... healthy weight. , The study is published online in ... Dietetics . , "Parents have a hard time changing ... author Kyung Rhee, MD, and an assistant adjunct professor ...
(Date:7/21/2014)... Aqua satellites detected 154 hotspots in areas across Riau ... fires had increased again following a decline in rainfall. ... was far higher than what had been reported one ... The hotspots were scattered in six regencies and municipalities, ... Smoke and the related haze it creates could potentially ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2
... A newly identified defect in a DNA repair system might ... a key chemotherapy drug, possibly putting them at greater risk ... by St. Jude Children,s Research Hospital scientists. The ... acute lymphoblastic leukemia (ALL) patients who are at higher risk ...
... compound tested by UT Southwestern Medical Center investigators destroys several ... 30 million people in the worldwide pandemic of 1918. ... of a human antiviral protein - could potentially be developed ... that tends to mutate into strains resistant to anti-influenza drugs. ...
... [Brown University] Take your time. Hold your horses. ... arguably equal choices, they need time to deliberate. In ... for Parkinson,s disease, that process sometimes doesn,t kick in, ... happens has led scientists to a detailed explanation of ...
Cached Biology News:Newly identified DNA repair defect linked to increased risk of leukemia relapse 2Newly identified DNA repair defect linked to increased risk of leukemia relapse 3Compound kills highly contagious flu strain by activating antiviral protein 2DBS studies show how brain buys time for tough choices 2DBS studies show how brain buys time for tough choices 3
UGT1A7 (E-15)...
... peptide corresponding to the third cytoplasmic loop ... conjugated to KLH. The immunizing peptide has ... gene. Physical form: Solution in phosphate ... azide. Titertest method: IHC (p). ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: